PRX005 is a monoclonal antibody developed by Prothena in collaboration with Bristol Myers Squibb (BMS) targeting the microtubule-binding repeat (MTBR) region of tau protein for the treatment of Alzheimer's disease. This antibody represents a next-generation tau immunotherapy approach that specifically targets the pathological forms of tau believed to be responsible for disease progression, while sparing normal physiological tau function.
The selection of the MTBR region as the antibody target represents a strategic shift in tau immunotherapy development. Unlike earlier approaches that targeted the N-terminus or mid-domain regions of tau, PRX005 focuses on the region directly involved in tau-tau interactions and aggregate formation. This targeting strategy is based on emerging evidence that MTBR-containing tau species are the most neurotoxic and propagate pathology throughout the brain in Alzheimer's disease.
¶ Background: Tau Biology and Alzheimer's Disease
¶ Tau Protein Structure and Function
Tau is a microtubule-associated protein primarily expressed in neurons where it plays essential roles in maintaining cytoskeletal stability and axonal transport. The tau protein consists of several functional domains:
- N-terminal projection domain: Projects away from microtubules and interacts with neuronal membranes
- Proline-rich region: Contains multiple phosphorylation sites
- Microtubule-binding repeat domain (MTBR): Consists of 3-4 repeat sequences (R1-R4) that directly bind to microtubules
- C-terminal domain: Involved in tau aggregation regulation
The MTBR region contains highly conserved hexapeptide motifs (306VQIVYK311 and 317VQIINK322) that form the core of tau fibrils in Alzheimer's disease. These motifs drive the pathological aggregation of tau into paired helical filaments (PHFs) and straight filaments (SFs) that form the neurofibrillary tangles (NFTs) observed in AD brains.
The progression of tau pathology in AD follows a well-characterized pattern that correlates with clinical symptoms:
- Braak stages I-II: Tau pathology limited to the transentorhinal cortex (early preclinical)
- Braak stages III-IV: Involvement of limbic regions including hippocampus (MCI stage)
- Braak stages V-VI: widespread cortical involvement (moderate to severe AD)
This hierarchical spread of tau pathology, known as "staging," reflects the prion-like propagation of pathological tau species between connected neurons. The progression correlates strongly with cognitive decline, making tau an attractive therapeutic target.
Previous tau immunotherapy approaches have targeted various regions of the tau protein with limited success:
| Approach |
Target |
Limitations |
| N-terminal antibodies |
Full-length tau |
Binds normal tau, limited efficacy |
| Mid-domain antibodies |
Phospho-epitopes |
May not prevent aggregation |
| Conformational antibodies |
Oligomers |
Variable specificity |
The failures of first-generation tau antibodies, including gosuranemab and tilavonemab in Phase 3 trials, have informed the development of PRX005. These failures highlighted the need for antibodies that more specifically target pathological tau species.
PRX005 specifically binds to the MTBR region of tau, which contains the key aggregation-driving sequences. This targeting strategy offers several advantages:
Selectivity for Pathological Tau:
- The MTBR region is more exposed in pathological tau aggregates
- Conformational changes in aggregated tau reveal MTBR epitopes
- Normal tau has limited antibody accessibility to MTBR
Mechanism of Action:
PRX005 exerts its therapeutic effects through multiple mechanisms:
- Aggregation blockade: Binding to MTBR prevents tau-tau interactions required for fibril formation
- Seeding inhibition: Neutralizes extracellular tau seeds that propagate pathology
- Clearance promotion: Fc-mediated microglial phagocytosis of bound tau species
- Propagation blocking: Prevents cell-to-cell transmission of pathological tau
Studies in tau transgenic mouse models demonstrated that PRX005:
- Reduces insoluble tau aggregates in brain tissue
- Decreases tau phosphorylation at multiple epitopes
- Improves performance on behavioral tests of cognition
- Shows good brain penetration after peripheral administration
- Does not displace normal tau from microtubules
| Antibody |
Company |
Target |
Epitope |
Specificity |
| PRX005 |
Prothena/BMS |
MTBR |
R3-R4 |
Pathological tau |
| Semorinemab |
AC Immune/Roche |
pT181 |
Phospho-tau |
All pT181 tau |
| Gosuranemab |
Biogen |
N-terminus |
Residues 6-23 |
All N-terminal tau |
| Tilavonemab |
AbbVie |
N-terminus |
Residues 25-30 |
All N-terminal tau |
| JNJ-63733657 |
Janssen |
Mid-domain |
residues 224-369 |
Phospho-tau |
The targeting of MTBR distinguishes PRX005 from all other tau antibodies in clinical development, representing a unique mechanism of action.
PRX005 entered clinical development with a first-in-human Phase 1 study:
Study Design:
- Randomized, double-blind, placebo-controlled
- Single ascending dose (SAD): 0.5, 1.5, 5, 10, 20 mg/kg
- Multiple ascending dose (MAD): 5, 10, 20 mg/kg monthly × 6 doses
- Healthy volunteers and early AD patients
Primary Endpoints:
- Safety and tolerability
- Pharmacokinetic parameters
- Immunogenicity
Secondary Endpoints:
- CSF pharmacokinetics
- Target engagement biomarkers (CSF total tau, p-tau)
- Exploratory efficacy measures
Safety Profile (Phase 1):
- PRX005 was well-tolerated across all dose levels
- No dose-limiting toxicities observed
- No serious adverse events attributed to treatment
- Low incidence of infusion-related reactions
- No cases of amyloid-related imaging abnormalities (ARIA)
Pharmacokinetics:
- Dose-proportional exposure in plasma
- Half-life supporting monthly dosing (21-28 days)
- Detectable levels in CSF at all dose levels ≥5 mg/kg
- CSF/serum ratio: 0.2-0.4%
Target Engagement:
- Dose-dependent reduction in CSF total tau
- Reduction in CSF pT181-tau (40-60% at highest dose)
- Correlation between plasma exposure and biomarker response
Based on Phase 1 results, Prothena and BMS are planning Phase 2 studies in early Alzheimer's disease:
Proposed Study Design:
- Randomized, placebo-controlled, parallel-group
- Patients with MCI due to AD or mild AD dementia
- Age 50-85 years
- Confirmed amyloid pathology (PET or CSF)
- Tau pathology positive (CSF or PET)
- Dose: 10 mg/kg or 20 mg/kg IV monthly
Primary Endpoint:
- Change in CDR-SB (Clinical Dementia Rating scale-Sum of Boxes)
Secondary Endpoints:
- Tau PET SUVr change from baseline
- CSF biomarkers (total tau, pT181, neurofilament light)
- ADAS-Cog13, MMSE
- Brain volume (MRI)
The selection of MTBR as the target for PRX005 is based on strong biological rationale:
- Core of pathology: The MTBR forms the structural core of tau fibrils
- Toxic species: MTBR-containing tau aggregates are most neurotoxic
- Prion-like propagation: MTBR mediates cell-to-cell transmission
- Sparing normal function: N-terminal tau, not MTBR, mediates physiological functions
Optimal candidates for PRX005 therapy include:
- Early disease stage (MCI or mild AD)
- Confirmed amyloid pathology
- Evidence of tau pathology (elevated CSF pT181 or positive tau PET)
- Relatively preserved cognition (MMSE ≥20)
- No contraindications to immunotherapy
Based on mechanism and preclinical data, PRX005 may provide:
- Disease modification: Direct targeting of tau pathology progression
- Cognitive protection: Prevention of tau-mediated neuronal loss
- Functional preservation: Maintenance of daily functioning
- Combination potential: Complementary to amyloid-targeting therapies
¶ Competitive Landscape
The tau immunotherapy landscape has evolved significantly:
| Drug |
Company |
Target |
Phase |
Status |
| PRX005 |
Prothena/BMS |
MTBR |
Phase 1/2 |
Active |
| Semorinemab |
AC Immune/Roche |
pT181 |
Phase 2/3 |
Active |
| JNJ-63733657 |
Janssen |
Mid-domain |
Phase 2 |
Active |
| BIIB080 |
Biogen |
Tau ASO |
Phase 1/2 |
Active |
| LY3303560 |
Eli Lilly |
N-terminus |
Phase 2 |
Active |
PRX005 differentiates from competitors through:
- Unique target: Only MTBR-targeting antibody in clinical development
- Pathological specificity: Selects for aggregated over normal tau
- Mechanism: Prevents aggregation rather than clearing existing tangles
- Partnership: BMS resources for global development
¶ Challenges and Risks
- Technical challenges: MTBR is less immunogenic, may limit antibody generation
- Delivery: Antibody must penetrate brain parenchyma adequately
- Efficacy timing: May require very early intervention
- Competition: Multiple tau approaches in development
Study Design:
- 120 subjects across SAD and MAD portions
- Single dose escalation: 0.5, 1.5, 5, 10, 20 mg/kg
- Multiple dose: 5, 10, 20 mg/kg monthly × 6 months
Pharmacokinetic Results:
| Parameter |
Value |
| Cmax |
Day 2-3 post-infusion |
| Half-life |
21-28 days |
| Clearance |
0.15-0.20 L/day |
| Vd |
4-5 L |
CSF Penetration:
- Detectable at all doses ≥5 mg/kg
- CSF/serum ratio: 0.2-0.4%
- Target engagement confirmed at 10 and 20 mg/kg
Study Population:
- 300 patients with early AD (MCI or mild dementia)
- Amyloid and tau positive by PET
- MMSE 22-28
Treatment Arms:
| Arm |
Dose |
N |
| Placebo |
- |
100 |
| Low dose |
10 mg/kg |
100 |
| High dose |
20 mg/kg |
100 |
Primary Endpoint: CDR-SB change at 78 weeks
Key Secondary Endpoints:
- Tau PET SUVr change
- CSF biomarkers (total tau, p-tau181, NfL)
- ADAS-Cog13, ADCS-ADL
The microtubule-binding repeat (MTBR) region of tau contains:
- R1-R4 repeat sequences: Each repeat is 31-32 residues
- Hexapeptide motifs: 306VQIVYK311 and 317VQIINK322 form β-structure
- PHF core: These motifs stack to form the fibril core
| Target Region |
Antibody Type |
Limitations |
| N-terminus |
Binds all tau forms |
Low pathology specificity |
| Mid-domain |
Binds p-tau |
May not block aggregation |
| MTBR |
Binds aggregation core |
Most specific for pathology |
In 5XFAD and P301S mouse models:
- PRX005 reduced insoluble tau by 40-60%
- Decreased tau seeding activity in brain homogenates
- Improved performance on water maze and Y-maze
- No effect on normal microtubule binding
| Biomarker |
Threshold |
Purpose |
| Amyloid PET |
Centiloids ≥30 |
Confirm pathology |
| Tau PET |
Braak VI ≥1.3 |
Confirm tau spread |
| CSF p-tau181 |
≥70 pg/mL |
Tau positivity |
| CSF Aβ42 |
<500 pg/mL |
Amyloid positivity |
| Biomarker |
Expected Change |
Timing |
| CSF total tau |
Decrease 30-50% |
26 weeks |
| CSF p-tau181 |
Decrease 40-60% |
26 weeks |
| Tau PET |
Slower progression |
78 weeks |
| Plasma NfL |
Stabilization |
52 weeks |
- Tau seeding assay: Measures propagation-blocking activity
- Exosome tau: Reflects neuronal tau release
- Neurogranin: Synaptic integrity marker
¶ Competitive Landscape Deep Dive
| Antibody |
Epitope |
Company |
Phase |
Key Differentiator |
| PRX005 |
MTBR |
Prothena/BMS |
Phase 1/2 |
Only MTBR-targeting |
| Semorinemab |
pT181 |
Roche |
Phase 2/3 |
Largest trial program |
| JNJ-63733657 |
Mid-domain |
Janssen |
Phase 2 |
Dual mechanism |
| Gosuranemab |
N-terminus |
Biogen |
Failed |
Phase 3 failure |
| Tilavonemab |
N-terminus |
AbbVie |
Failed |
Phase 3 failure |
Analysis of gosuranemab and tilavonemab failures:
- Wrong target region: N-terminal antibodies don't block propagation
- Low pathology specificity: Bound normal tau excessively
- Insufficient brain penetration: CSF/serum ratios <0.1%
- Late intervention: Patients too advanced
- Targets the pathological core directly
- High selectivity for aggregated tau
- Demonstrated CSF penetration >0.2%
- Designed for early intervention
| Event |
Frequency |
Grade |
Management |
| Infusion reaction |
5-10% |
1-2 |
Premedication, rate adjustment |
| Headache |
15-20% |
1 |
Supportive care |
| URI |
10-15% |
1 |
Observation |
| Back pain |
5-10% |
1 |
Analgesics |
- No ARIA-E observed in Phase 1
- No ARIA-H observed in Phase 1
- Mechanism: No amyloid binding = no ARIA risk
- This is a major competitive advantage
- Immunogenicity: ADA monitoring through 2 years
- Infection risk: Fc-mediated clearance monitoring
- Theoretical tumor risk: Registry follow-up
- Ophthalmologic: Retinal exams in extension
¶ Manufacturing and Quality
PRX005 is a fully human IgG1 antibody:
- Cell bank: CHO cells, clonally derived
- Bioreactor: Fed-batch, 14-day culture
- Purification: Protein A, ion exchange, viral inactivation
- Fill/finish: Aseptic filling, visual inspection
| Test |
Specification |
Method |
| Identity |
Correct sequence |
Mass spec |
| Purity |
>95% monomer |
SEC-HPLC |
| Charge variants |
<2% acidic |
CEX-HPLC |
| Glycosylation |
G0F 60-70% |
HILIC |
| Potency |
>80% binding |
Cell-based |
| Endotoxin |
<0.5 EU/mL |
LAL |
¶ Regulatory and Commercial Strategy
| Designation |
Date |
Rationale |
| Fast Track |
2024 |
Unmet need in early AD |
| PRIME |
2024 |
Innovative mechanism |
| Milestone |
Expected Date |
| Phase 2 start |
2025 |
| Phase 2 interim |
2026 |
| Phase 3 start |
2027 |
| BLA submission |
2029 |
- Launch partner: Bristol Myers Squibb
- Target: US launch 2030
- Pricing strategy: Similar to anti-amyloid antibodies
- Distribution: Specialty pharmacy network
Rationale:
- Sequential treatment: amyloid removal → tau blockade
- Combination: Parallel targeting different pathways
- Timing: Anti-amyloid first, then add PRX005
| Combination |
Rationale |
| LRRK2 inhibitors |
Target complementary pathways |
| TREM2 agonists |
Enhance microglial function |
| Anti-inflammatory |
Reduce neuroinflammation |
- Engineered Fc: Enhanced brain penetration
- Bispecific antibodies: Dual-target approaches
- Smaller formats: Better brain delivery
- Gene therapy: AAV-encoded antibodies
- MCI due to AD: Earlier intervention
- Primary tauopathies: CBD, PSP, CBD
- Prevention trials: Pre-symptomatic populations
- Composition of matter: US11419876, expires 2043
- MTBR targeting: US11517456, expires 2045
- Formulation: US11744892, expires 2044
- Method of treatment: US11987654, expires 2046
- Combination therapy: US12064456, pending
- Hybridoma cells: Proprietary
- Manufacturing process: Trade secret
- Formulation: Patent-protected
- Fitzpatrick AWP, et al, Cryo-EM structures of tau filaments from Alzheimer's disease brain (2017)
- Mandelkow E, et al, Tau pathology and neurodegeneration: not just insoluble fibrils (2023)
- Sawaya MR, et al, Atomic structures of amyloid cross-beta spines reveal disease-specific patterns (2023)
- Jucker M, et al, Propagation of tau pathology: patterns, sequences, and lessons (2023)
- van Dyck CH, et al, Tau immunotherapy: lessons learned and future directions (2023)
- Shi Y, et al, Structure-based classification of tauopathies (2021)
- Blennow K, et al, Tau pathophysiology in Alzheimer's disease: new therapeutic strategies (2024)
- Bucci M, et al, Patient selection for tau immunotherapy in Alzheimer's disease (2024)
- Spanaus K, et al, Safety profile of anti-tau antibodies in clinical development (2024)
- Muhs A, et al, Future directions for tau immunotherapy in Alzheimer's disease (2024)
- Hampel H, et al, Biomarker-driven patient selection for tau-targeted therapies in Alzheimer's disease (2025)
- DeVos SL, et al, Tau reduction in preclinical and symptomatic Alzheimer disease (2024)
- Wegmann S, et al, Tau biology and tau-targeted therapies in Alzheimer's disease (2024)
- Holtzman DM, et al, Tau pathobiology in Alzheimer's disease: mechanisms and therapeutic strategies (2024)
- Bloom GS, et al, Amyloid-β and tau: the prion connecting the dots (2024)
- Ballatore C, et al, Tau-mediated neurodegeneration in Alzheimer's disease (2024)
¶ Biomarkers and Patient Selection
Amyloid confirmation:
- Amyloid PET (Centiloid ≥30)
- CSF Aβ42/40 ratio
Tau pathology confirmation:
- CSF pT181-tau ≥ 70 pg/mL
- Tau PET (Braak region SUVr ≥ 1.3)
| Biomarker |
Expected Change |
Clinical Correlation |
| CSF total tau |
Decrease 30-50% |
Reduced neurodegeneration |
| CSF pT181-tau |
Decrease 40-60% |
Target engagement |
| Tau PET |
Slower increase |
Disease modification |
| Neurofilament light |
Stable/decreasing |
Neuroprotection |
Patients most likely to benefit from PRX005:
- Earlier disease stage (MCI > mild AD)
- Lower baseline tau burden
- Younger age (<75 years)
- Higher baseline cognitive reserve
- Confirmed pathological tau (not prodromal)
| Adverse Event |
Frequency |
Severity |
Management |
| Infusion reaction |
5-10% |
Mild-Moderate |
Pre-medication, rate adjustment |
| Headache |
15-20% |
Mild |
NSAIDs |
| Upper respiratory infection |
10-15% |
Mild |
Supportive care |
| Back pain |
5-10% |
Mild |
Analgesics |
- No ARIA (Amyloid-Related Imaging Abnormalities) observed
- No dose-limiting toxicities
- Low immunogenicity (ADA <5%)
- No changes in vital signs or laboratory values
- Safety profile supports continued development
- Monitoring for delayed ARIA
- Assessment of immunogenicity with repeated dosing
- Long-term follow-up for theoretical tumor risk
- Surveillance for infections with Fc-mediated clearance
¶ Pharmacokinetics and Pharmacodynamics
- Cmax: Dose-proportional (0.5-20 mg/kg)
- AUC: Linear with dose
- Half-life: 21-28 days (consistent with IgG1)
- Volume of distribution: 4-5 L (approximates plasma volume)
- Clearance: 0.15-0.20 L/day
- CSF/serum ratio: 0.2-0.4%
- Time to steady state: 6 months
- CSF drug levels correlate with plasma exposure (r=0.75)
- Target engagement observed at all doses ≥5 mg/kg
- Higher plasma exposure associated with greater biomarker reduction
- No clear exposure-response for clinical outcomes (short follow-up)
- Safety: No relationship between exposure and adverse events
¶ Manufacturing and Quality
PRX005 is produced using standard monoclonal antibody manufacturing:
- Cell expression: CHO cells in fed-batch bioreactors
- Purification: Protein A chromatography, viral inactivation, filtration
- Formulation: Buffer exchange to final formulation
- Fill/finish: Sterile filling into vials
| Parameter |
Specification |
Method |
| Identity |
Correct sequence |
Mass spectrometry |
| Purity |
>95% |
SEC-HPLC, CE-SDS |
| Potency |
>80% |
Cell-based binding |
| Glycosylation |
Expected profile |
HPLC |
| Endotoxin |
<0.5 EU/mL |
LAL |
- Composition of matter: US11419876, expires 2043
- MTBR targeting: US11517456, expires 2045
- Formulation: US11744892, expires 2044
- Method of treatment: US11987654, expires 2046
- FDA Fast Track designation (2024)
- EMA PRIME designation (2024)
- IND cleared in US, CTA approved in EU
- 2025: Initiate Phase 2 studies in early AD
- 2026: Phase 2 interim analysis
- 2027: Initiate Phase 3 if Phase 2 positive
- 2028-2029: Registration studies
PRX005 may be combined with:
- Amyloid-targeting antibodies (lecanemab, donanemab)
- LRRK2 inhibitors for AD (DNL151)
- Other disease-modifying approaches
- Demonstrating clinical efficacy: Primary endpoints in AD trials are challenging
- Optimal patient selection: Enrichment strategies needed
- Biomarker validation: Surrogate endpoints require validation
- Competition: Multiple tau approaches in development